Johnson & Johnson, a leader in immunology, has developed ARGES, a new AI-powered tool that could transform endoscopic ...

Johnson & Johnson is normally a good buy for its dividend and the stability it offers. Over the past five years, however, the ...

Jason Najum talks to Srinivas Rao, CEO of Atai Life Sciences, a biotech company focused on mental health and psychedelic compounds.

The company announced on 18 February that the trial did not meet its primary endpoint measured by a depression rating scale, ...

Bryan Johnson, the American entrepreneur renowned for his anti-ageing endeavours, has disclosed the details of his latest ...

Stifel has initiated Compass Pathways (NASDAQ:CMPS) with a buy rating saying that stakeholders are starting to agree there is ...

Johnson & Johnson is well-diversified across thriving healthcare segments, with promising FDA approvals. Read why I assign a ...

Johnson & Johnson (NYSE ... Its key product, Caplyta, is an approved treatment for schizophrenia and depression related to bipolar I or II disorder. It may also soon obtain approval for major ...

In this article, we are going to take a look at where Johnson & Johnson (NYSE ... During major crises such as the Great Depression, the 2008 financial crisis, and the COVID-19 pandemic, the ...

Who is Bryan Johnson, the tech CEO who spent millions on anti-ageing venture - The entrepreneur has recently revealed what he ...